A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas.
1p/19q codeletion
gene signature
glioma
treatment response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Jun 2023
06 Jun 2023
Historique:
received:
25
04
2023
revised:
30
05
2023
accepted:
01
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
IDH mutant and 1p/19q codeleted oligodendrogliomas are the gliomas associated with the best prognosis. However, despite their sensitivity to treatment, patient survival remains heterogeneous. We aimed to identify gene expressions associated with response to treatment from a national cohort of patients with oligodendrogliomas, all treated with radiotherapy +/- chemotherapy. We extracted total RNA from frozen tumor samples and investigated enriched pathways using KEGG and Reactome databases. We applied a stability selection approach based on subsampling combined with the lasso-pcvl algorithm to identify genes associated with progression-free survival and calculate a risk score. We included 68 patients with oligodendrogliomas treated with radiotherapy +/- chemotherapy. After filtering, 1697 genes were obtained, including 134 associated with progression-free survival: 35 with a better prognosis and 99 with a poorer one. Eight genes (ST3GAL6, QPCT, NQO1, EPHX1, CST3, S100A8, CHI3L1, and OSBPL3) whose risk score remained statistically significant after adjustment for prognostic factors in multivariate analysis were selected in more than 60% of cases were associated with shorter progression-free survival. We found an eight-gene signature associated with a higher risk of rapid relapse after treatment in patients with oligodendrogliomas. This finding could help clinicians identify patients who need more intensive treatment.
Sections du résumé
BACKGROUND
BACKGROUND
IDH mutant and 1p/19q codeleted oligodendrogliomas are the gliomas associated with the best prognosis. However, despite their sensitivity to treatment, patient survival remains heterogeneous. We aimed to identify gene expressions associated with response to treatment from a national cohort of patients with oligodendrogliomas, all treated with radiotherapy +/- chemotherapy.
METHODS
METHODS
We extracted total RNA from frozen tumor samples and investigated enriched pathways using KEGG and Reactome databases. We applied a stability selection approach based on subsampling combined with the lasso-pcvl algorithm to identify genes associated with progression-free survival and calculate a risk score.
RESULTS
RESULTS
We included 68 patients with oligodendrogliomas treated with radiotherapy +/- chemotherapy. After filtering, 1697 genes were obtained, including 134 associated with progression-free survival: 35 with a better prognosis and 99 with a poorer one. Eight genes (ST3GAL6, QPCT, NQO1, EPHX1, CST3, S100A8, CHI3L1, and OSBPL3) whose risk score remained statistically significant after adjustment for prognostic factors in multivariate analysis were selected in more than 60% of cases were associated with shorter progression-free survival.
CONCLUSIONS
CONCLUSIONS
We found an eight-gene signature associated with a higher risk of rapid relapse after treatment in patients with oligodendrogliomas. This finding could help clinicians identify patients who need more intensive treatment.
Identifiants
pubmed: 37370678
pii: cancers15123067
doi: 10.3390/cancers15123067
pmc: PMC10296584
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2006 Jun 20;24(18):2707-14
pubmed: 16782910
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
J Hematol Oncol. 2020 Oct 21;13(1):141
pubmed: 33087132
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Aging (Albany NY). 2021 Jun 8;13(11):15459-15478
pubmed: 34148033
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Biol Chem. 2018 Jun 27;399(7):661-672
pubmed: 29894296
Eur J Cancer. 2006 Oct;42(15):2499-503
pubmed: 16914310
Neurobiol Dis. 2007 Mar;25(3):455-63
pubmed: 17223348
Brain Res. 2022 Aug 15;1789:147952
pubmed: 35623391
Front Immunol. 2022 Oct 31;13:1028937
pubmed: 36389681
Theranostics. 2020 Aug 8;10(22):10078-10091
pubmed: 32929335
Neuro Oncol. 2017 Jun 1;19(6):786-795
pubmed: 28340142
Neuro Oncol. 2016 Mar;18(3):388-400
pubmed: 26354927
Neuro Oncol. 2016 Sep;18(9):1253-64
pubmed: 27006175
Oncologist. 2022 May 6;27(5):414-423
pubmed: 35522558
Neuro Oncol. 2014 Sep;16(9):1244-54
pubmed: 24723566
Sci Rep. 2021 Sep 28;11(1):19178
pubmed: 34584127
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
Nat Commun. 2016 Apr 19;7:11263
pubmed: 27090007
Neuro Oncol. 2019 Dec 17;21(12):1519-1528
pubmed: 31832685
Stat Med. 2016 Jul 10;35(15):2561-73
pubmed: 26970107
Int J Cancer. 2019 Jul 15;145(2):450-460
pubmed: 30613961
Lancet Oncol. 2021 Jun;22(6):813-823
pubmed: 34000245
J Clin Invest. 2021 Aug 16;131(16):
pubmed: 34228644
Cancer Res. 2016 Feb 1;76(3):525-34
pubmed: 26762204
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Aging (Albany NY). 2022 Mar 29;14(6):2819-2854
pubmed: 35349479
Cancer Res. 2018 Nov 1;78(21):6345
pubmed: 30385611
Nat Med. 2022 Apr;28(4):752-765
pubmed: 35411077
Oncologist. 2021 May;26(5):e838-e846
pubmed: 33524191
Front Neurosci. 2016 Jul 28;10:344
pubmed: 27516732
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2022 Feb 1;40(4):403-426
pubmed: 34898238
Front Genet. 2021 Aug 26;12:666106
pubmed: 34512713
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237